Department of Internal Medicine, A.O. Fatebenefratelli e Oftalmico, Milan, Italy.
Liver Int. 2015 Jan;35 Suppl 1:35-43. doi: 10.1111/liv.12712.
Although HCV infection mainly induces liver injury, chronic disease is systemic. Moreover, host and viral factors, as well as comorbidities, may influence the chance of achieving a sustained virological response or disease outcome. Although there are sufficient data on the use of peg-interferon and ribavirin in patients with comorbidities, there is very little data on first generation protease inhibitors, which include significant drug-drug interactions and have therefore been administered with caution in these patients. The availability of new, more effective direct acting antivirals should significantly change this scenario. All these issues are discussed in this review.
虽然 HCV 感染主要引起肝脏损伤，但慢性疾病是全身性的。此外，宿主和病毒因素以及合并症可能会影响实现持续病毒学应答或疾病结局的机会。虽然有足够的数据表明在合并症患者中使用聚乙二醇干扰素和利巴韦林，但关于第一代蛋白酶抑制剂的数据非常少，这些抑制剂包括显著的药物相互作用，因此在这些患者中谨慎使用。新型、更有效的直接作用抗病毒药物的出现应该会显著改变这种情况。所有这些问题都在本综述中进行了讨论。
